HK1067562A1 - Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents - Google Patents
Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agentsInfo
- Publication number
- HK1067562A1 HK1067562A1 HK05101068.0A HK05101068A HK1067562A1 HK 1067562 A1 HK1067562 A1 HK 1067562A1 HK 05101068 A HK05101068 A HK 05101068A HK 1067562 A1 HK1067562 A1 HK 1067562A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- chronic myelogenous
- myelogenous leukemia
- sti571
- treatment
- intolerant
- Prior art date
Links
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 title abstract 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 title abstract 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 title abstract 3
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 title abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002411 imatinib Drugs 0.000 title abstract 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 title abstract 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 title abstract 2
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31696701P | 2001-09-05 | 2001-09-05 | |
| PCT/IB2002/003992 WO2003020252A2 (en) | 2001-09-05 | 2002-09-05 | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1067562A1 true HK1067562A1 (en) | 2005-04-15 |
Family
ID=23231501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK05101068.0A HK1067562A1 (en) | 2001-09-05 | 2005-02-08 | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| HK10109892A HK1143732A1 (en) | 2001-09-05 | 2010-10-19 | Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10109892A HK1143732A1 (en) | 2001-09-05 | 2010-10-19 | Homoharringtonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to protein kinase inhibitors other than sti 571 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6987103B2 (es) |
| EP (2) | EP1443933B1 (es) |
| JP (2) | JP4794816B2 (es) |
| AT (2) | ATE451106T1 (es) |
| AU (1) | AU2002337410A1 (es) |
| CA (1) | CA2459822C (es) |
| CY (2) | CY1109799T1 (es) |
| DE (1) | DE60234708D1 (es) |
| DK (2) | DK2177223T3 (es) |
| ES (2) | ES2334774T3 (es) |
| HK (2) | HK1067562A1 (es) |
| PT (2) | PT2177223E (es) |
| WO (1) | WO2003020252A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| AU2003291882A1 (en) * | 2002-12-06 | 2004-06-30 | Shire Biochem Inc. | Pharmaceutical combinations and methods for the treatment of leukemia |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| MX2008012971A (es) * | 2006-04-07 | 2008-10-15 | Novartis Ag | Combinacion que comprende a) un compuesto de pirimidil-amino-benza mida, y b) un inhibidor de cinasa thr315lle. |
| WO2008017024A2 (en) * | 2006-08-02 | 2008-02-07 | Universtiy Of South Florida | Method of treating chronic myelogenous leukemia cells |
| JP5550546B2 (ja) * | 2007-04-13 | 2014-07-16 | ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド | 経口セファロタキシン剤形 |
| EP2229160A1 (en) * | 2007-12-07 | 2010-09-22 | ChemGenex Pharmaceuticals, Inc. | Leukemic stem cell ablation |
| JP5617175B2 (ja) | 2008-04-17 | 2014-11-05 | 富士電機株式会社 | ワイドバンドギャップ半導体装置とその製造方法 |
| BR112013033674A2 (pt) * | 2011-06-29 | 2018-07-17 | Penn State Res Found | composições, métodos e kits para tratamento da leucemia |
| CA2845585C (en) | 2011-08-30 | 2020-02-18 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| MX2018000016A (es) | 2015-07-02 | 2019-01-31 | Otsuka Pharma Co Ltd | Composiciones farmaceuticas liofilizadas. |
| AU2018310857A1 (en) | 2017-08-03 | 2020-02-13 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
-
2002
- 2002-09-05 DE DE60234708T patent/DE60234708D1/de not_active Expired - Lifetime
- 2002-09-05 WO PCT/IB2002/003992 patent/WO2003020252A2/en active Application Filing
- 2002-09-05 AU AU2002337410A patent/AU2002337410A1/en not_active Abandoned
- 2002-09-05 CA CA2459822A patent/CA2459822C/en not_active Expired - Fee Related
- 2002-09-05 AT AT02772653T patent/ATE451106T1/de active
- 2002-09-05 ES ES02772653T patent/ES2334774T3/es not_active Expired - Lifetime
- 2002-09-05 DK DK09172828.7T patent/DK2177223T3/da active
- 2002-09-05 DK DK02772653.8T patent/DK1443933T3/da active
- 2002-09-05 EP EP02772653A patent/EP1443933B1/en not_active Expired - Lifetime
- 2002-09-05 EP EP20090172828 patent/EP2177223B9/en not_active Expired - Lifetime
- 2002-09-05 PT PT09172828T patent/PT2177223E/pt unknown
- 2002-09-05 JP JP2003524561A patent/JP4794816B2/ja not_active Expired - Fee Related
- 2002-09-05 ES ES09172828T patent/ES2383771T3/es not_active Expired - Lifetime
- 2002-09-05 AT AT09172828T patent/ATE548041T1/de active
- 2002-09-05 PT PT02772653T patent/PT1443933E/pt unknown
-
2003
- 2003-03-27 US US10/397,267 patent/US6987103B2/en active Active
-
2005
- 2005-02-08 HK HK05101068.0A patent/HK1067562A1/xx not_active IP Right Cessation
-
2009
- 2009-02-02 JP JP2009021692A patent/JP2009102408A/ja active Pending
-
2010
- 2010-02-10 CY CY20101100126T patent/CY1109799T1/el unknown
- 2010-10-19 HK HK10109892A patent/HK1143732A1/xx not_active IP Right Cessation
-
2012
- 2012-06-06 CY CY20121100501T patent/CY1112817T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2383771T3 (es) | 2012-06-26 |
| ATE548041T1 (de) | 2012-03-15 |
| PT1443933E (pt) | 2010-01-27 |
| WO2003020252A3 (en) | 2003-06-19 |
| CA2459822A1 (en) | 2003-03-13 |
| US6987103B2 (en) | 2006-01-17 |
| EP2177223A3 (en) | 2010-05-19 |
| US20040019036A1 (en) | 2004-01-29 |
| EP1443933B1 (en) | 2009-12-09 |
| ES2334774T3 (es) | 2010-03-16 |
| AU2002337410A1 (en) | 2003-03-18 |
| PT2177223E (pt) | 2012-05-23 |
| JP2009102408A (ja) | 2009-05-14 |
| JP4794816B2 (ja) | 2011-10-19 |
| DK1443933T3 (da) | 2010-01-25 |
| EP2177223A2 (en) | 2010-04-21 |
| WO2003020252A2 (en) | 2003-03-13 |
| CY1109799T1 (el) | 2014-09-10 |
| DE60234708D1 (de) | 2010-01-21 |
| HK1143732A1 (en) | 2011-01-14 |
| EP2177223B1 (en) | 2012-03-07 |
| JP2005508896A (ja) | 2005-04-07 |
| DK2177223T3 (da) | 2012-04-10 |
| EP2177223B9 (en) | 2012-10-31 |
| ATE451106T1 (de) | 2009-12-15 |
| EP1443933A2 (en) | 2004-08-11 |
| CY1112817T1 (el) | 2016-02-10 |
| CA2459822C (en) | 2013-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1067562A1 (en) | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents | |
| ZA200407813B (en) | Medicament for preventing and/or treating chronic rejection. | |
| HK1073608A1 (en) | Treatment of alpha-galactosidase a deficiency | |
| HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| PT1687284E (pt) | Inibidores de quinase p-38 | |
| IL141067A0 (en) | Treatment of addiction and addiction-related behavior | |
| IL162447A0 (en) | Methods for slowing senescence and treating and preventing diseases associated with senescence | |
| HK1087351A1 (en) | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit | |
| DK1355669T3 (da) | Forbedret kognitiv træning | |
| MX2008009579A (es) | Metodo para el tratamiento de dolor neuropatico. | |
| IL161501A0 (en) | Methods of preventing and treating flavivirus infection in animals | |
| WO2001091745A3 (en) | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions | |
| WO2006102611A3 (en) | Therapeutic agents for the treatment of leukemia | |
| MY122838A (en) | Treating allergic and inflammatory conditions | |
| ATE517617T1 (de) | Behandlung von parkinson erkrankung mit kape | |
| EP1662875A4 (en) | CHELERYTHRINE, ANALOGUES THEREOF AND THEIR USE IN TREATING DISORDER AND OTHER COGNITIVE DISORDERS | |
| ATE473001T1 (de) | Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba | |
| DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma | |
| PL365565A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| GB9827121D0 (en) | Agent for lowering endothelin levels | |
| ZA200208272B (en) | Treatment of fibromyalgia and chronic fatigue syndrome. | |
| NO20004363L (no) | Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme | |
| WO2003030722A3 (en) | Magnetic field enhancement of tumor treatment | |
| MXPA03011705A (es) | Antihistaminas para el tratamiento de congestion nasal y obstruccion nasal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180905 |